Loading stock…

Xero Limited (XRO) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

XROXero

Revenue FY26$1.6B

GROWTH RATING↗

VERY STRONG93 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+22%9

Revenue, next 1Y+30%9

Revenue, next 3Y, CAGR+24%9

Revenue, next 5Y, CAGR+19%9

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+26%8

EPS growth, FY28E+82%10

EPS growth, FY29E+51%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 93% of companies worldwide.

Revenue grew 22%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 24%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 22%/yr over the last 3 years and is set to keep growing around 24%/yr.

The runway holds up: revenue is set to grow 19%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 51%/yr vs revenue 24%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

XROXero

Total return Current191%

Price return Current191%

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-24%1

3-month return-24%1

YTD return-51%1

MID & LONG-TERM▾SCORE

% of 52-week high37%1

1-year return-64%1

3-year return-50%1

5-year return-60%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-50% over three years and -60% over five), behind 90% of the market.

It's down 64% over the past year, now 63% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-24%), over three months (-24%) and so far this year (-51%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Xero. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

XROXero

Revenue FY26$1.6B

GROWTH RATING↗

VERY STRONG93 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+22%9

Revenue, next 1Y+30%9

Revenue, next 3Y, CAGR+24%9

Revenue, next 5Y, CAGR+19%9

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+26%8

EPS growth, FY28E+82%10

EPS growth, FY29E+51%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 93% of companies worldwide.

Revenue grew 22%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 24%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 22%/yr over the last 3 years and is set to keep growing around 24%/yr.

The runway holds up: revenue is set to grow 19%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 51%/yr vs revenue 24%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

XROXero

Total return Current191%

Price return Current191%

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-24%1

3-month return-24%1

YTD return-51%1

MID & LONG-TERM▾SCORE

% of 52-week high37%1

1-year return-64%1

3-year return-50%1

5-year return-60%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-50% over three years and -60% over five), behind 90% of the market.

It's down 64% over the past year, now 63% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-24%), over three months (-24%) and so far this year (-51%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Xero. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Xero Limited

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Xero. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Xero. Get the full investment case.

Premium